Dianthus Therapeutics DNTH Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's stock-based comp?
- Dianthus Therapeutics (DNTH) reported stock-based comp of $10.6M in Q1 2026.
- How has Dianthus Therapeutics's stock-based comp changed year-over-year?
- Dianthus Therapeutics's stock-based comp increased by 99.5% year-over-year, from $5.32M to $10.6M.
- What is the long-term trend for Dianthus Therapeutics's stock-based comp?
- Over 2 years (2021 to 2024), Dianthus Therapeutics's stock-based comp has grown at a 11.8% compound annual growth rate (CAGR), from $10.31M to $12.89M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.